Market research
CNCE Concert Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 402M
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- 0.0%
- Beta
- 0.52
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 402M
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- 0.0%
- Beta
- 0.52
About
About Concert Pharmaceuticals Inc
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Research context
Concert Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CNCE discussion.
5 years, 6 months ago
Concert Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 53.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.0.
Concert Pharmaceuticals, Inc's total revenue sank by 46.2% to $7K since the same quarter in the previous year.
Its net income has dropped by 9.3% to $-22M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-16M since the same quarter in the previous year.
Based on the above factors, Concert Pharmaceuticals, Inc gets an overall score of 1/5.